Bristol Myers Squibb (CELG-RI) EPS (Basic) Growth (3y) (2012 - 2026)
Powered by 
Analysis
Bristol Myers Squibb (CELG-RI) EPS (Basic) Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.39 Bn | 620.63 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 445.66 Bn | 439.09 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 357.45 Bn | 350.31 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 267.58 Bn | 259.89 Bn | 11.24 Bn | 14.72% |
| 5 | Pfizer | 156.75 Bn | 145.05 Bn | 10.94 Bn | -28.08% |
| 6 | Sanofi | 52.14 Bn | 44.75 Bn | 10.79 Bn | -36.03% |
| 7 | Revolution Medicines | 42.91 Bn | 42.91 Bn | - | - |
| 8 | Incyte | 24.62 Bn | 20.08 Bn | 1.57 Bn | 47.44% |
| 9 | United Therapeutics | 21.28 Bn | 18.62 Bn | 683.80 Mn | 12.25% |
| 10 | Bristol Myers Squibb | 232.18 Mn | -10.83 Bn | 9.25 Bn | 17.84% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.84% |
| Mar 31, 2026 | 6.77% |
| Dec 31, 2025 | -17.50% |
| Sep 30, 2025 | 12.66% |
| Jun 30, 2025 | -1.25% |
| Mar 31, 2025 | 26.57% |
| Dec 31, 2024 | -67.26% |
| Sep 30, 2024 | -5.03% |
| Jun 30, 2024 | 20.36% |
| Mar 31, 2024 | -103.98% |
| Dec 31, 2023 | 29.90% |
| Sep 30, 2023 | 4.16% |
| Jun 30, 2023 | 210.97% |
| Mar 31, 2023 | 73.07% |
| Dec 31, 2022 | 52.25% |
| Sep 30, 2022 | -3.43% |
| Jun 30, 2022 | -8.68% |
| Mar 31, 2022 | -17.11% |
| Dec 31, 2021 | 14.63% |
| Sep 30, 2021 | -15.80% |